Sun, May 25, 2025
Volume 18, Issue 6 (Nov-Dec 2024)
mljgoums 2024, 18(6): 28-31 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hezarkhani S, Ghojoghi K, Hosseinzadeh S, Behnampour N, Fathabadi F, Hesari Z et al . Evaluation of serum adiponectin and leptin levels in type 2 diabetic patients: The potential role in predicting metabolic syndrome. mljgoums 2024; 18 (6) :28-31
URL: http://mlj.goums.ac.ir/article-1-1853-en.html
URL: http://mlj.goums.ac.ir/article-1-1853-en.html
Sharabeh Hezarkhani1 
, Khosro Ghojoghi2 , Sara Hosseinzadeh2 , Naser Behnampour3 , Farshid Fathabadi2 , Zahra Hesari4 , Hamid Reza Joshaghani2
, Khosro Ghojoghi2 , Sara Hosseinzadeh2 , Naser Behnampour3 , Farshid Fathabadi2 , Zahra Hesari4 , Hamid Reza Joshaghani2
1- Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran
3- Biostatistics Department, Faculty of Health, Golestan University of Medical Sciences, Gorgan, Iran
4- Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran ,hesari7@yahoo.com
2- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran
3- Biostatistics Department, Faculty of Health, Golestan University of Medical Sciences, Gorgan, Iran
4- Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran ,
Abstract: (850 Views)
Background: Leptin and adiponectin, two members of the adipokine family, play roles in increasing lipid metabolism and inhibiting lipogenesis. Reduced levels of these cytokines are associated with obesity and insulin resistance. This study aimed to determine the serum levels of leptin and adiponectin in type-2 diabetic patients with and without metabolic syndrome compared to a control group.
Methods: Three groups of individuals participated in this study: 47 type-2 diabetic patients with metabolic syndrome (DM+MetS), 25 type-2 diabetic patients without metabolic syndrome (DM-MetS), and 40 individuals with no history of diabetes or metabolic syndrome (Control group). Fasting blood samples were collected, and serum levels of fasting blood sugar, cholesterol, triglycerides, HDL-cholesterol, and LDL-cholesterol were measured using the enzymatic method. Blood pressure, height, and weight were recorded using stadiometers, while leptin and adiponectin levels were determined via enzyme-linked immunosorbent assay.
Results: A significant difference was observed between the DM+MetS group and the DM-MetS group in serum leptin (p = 0.004) and adiponectin (p < 0.001) levels. In patients with type-2 diabetes and metabolic syndrome, serum leptin (p = 0.530) and adiponectin (p < 0.001) levels were lower compared to the control group.
Conclusion: A decrease in the serum levels of key adipokines, such as leptin and adiponectin, in type-2 diabetic patients may serve as a predictor of metabolic syndrome.
Methods: Three groups of individuals participated in this study: 47 type-2 diabetic patients with metabolic syndrome (DM+MetS), 25 type-2 diabetic patients without metabolic syndrome (DM-MetS), and 40 individuals with no history of diabetes or metabolic syndrome (Control group). Fasting blood samples were collected, and serum levels of fasting blood sugar, cholesterol, triglycerides, HDL-cholesterol, and LDL-cholesterol were measured using the enzymatic method. Blood pressure, height, and weight were recorded using stadiometers, while leptin and adiponectin levels were determined via enzyme-linked immunosorbent assay.
Results: A significant difference was observed between the DM+MetS group and the DM-MetS group in serum leptin (p = 0.004) and adiponectin (p < 0.001) levels. In patients with type-2 diabetes and metabolic syndrome, serum leptin (p = 0.530) and adiponectin (p < 0.001) levels were lower compared to the control group.
Conclusion: A decrease in the serum levels of key adipokines, such as leptin and adiponectin, in type-2 diabetic patients may serve as a predictor of metabolic syndrome.
Research Article: Research Article |
Subject:
Biochemistry
Received: 2024/08/8 | Accepted: 2024/11/12 | Published: 2024/12/24 | ePublished: 2024/12/24
Received: 2024/08/8 | Accepted: 2024/11/12 | Published: 2024/12/24 | ePublished: 2024/12/24
References
1. Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022; 23(2):786. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Lau DC, Yan H, Dhillon B. Metabolic syndrome: a marker of patients at high cardiovascular risk. Can J Cardiol. 2006; 22 Suppl B(Suppl B): 85B-90B. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005; 115(5): 911-9; quiz 920. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Shin JA, Lee JH, Lim SY, Ha HS, Kwon HS, Park YM, et al. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig. 2013; 4(4): 334-43. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Trayhurn P, Bing C, Wood IS. Adipose tissue and adipokines--energy regulation from the human perspective. J Nutr. 2006; 136(7 Suppl): 1935S-1939S. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001; 86(5): 1930-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001; 50(5): 1126-33. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Michalska-Jakubus M, Sawicka K, Potembska E, Kowal M, Krasowska D. Clinical associations of serum leptin and leptin/adiponectin ratio in systemic sclerosis. Postepy Dermatol Alergol. 2019; 36(3): 325-338. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001; 7(8): 947-53. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Zhuo Q, Wang Z, Fu P, Piao J, Tian Y, Xu J, et al. Comparison of adiponectin, leptin and leptin to adiponectin ratio as diagnostic marker for metabolic syndrome in older adults of Chinese major cities. Diabetes Res Clin Pract. 2009; 84(1): 27-33. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Carbone F, La Rocca C, Matarese G. Immunological functions of leptin and adiponectin. Biochimie. 2012; 94(10): 2082-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372(6505): 425-32. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. van Dijk G. The role of leptin in the regulation of energy balance and adiposity. J Neuroendocrinol. 2001; 13(10): 913-21. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Huang L, Li C. Leptin: a multifunctional hormone. Cell Res. 2000; 10(2): 81-92. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Patel SB, Reams GP, Spear RM, Freeman RH, Villarreal D. Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Curr Hypertens Rep. 2008; 10(2): 131-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Miyanaga F, Ogawa Y, Ebihara K, Hidaka S, Tanaka T, Hayashi S, Masuzaki H, Nakao K. Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. Diabetologia. 2003; 46(10): 1329-37. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; National Heart, Lung, and Blood Institute; American Heart Association. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004; 24(2): e13-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Sanjari M, Khodashahi M, Gholamhoseinian A, Shokoohi M. Association of adiponectin and metabolic syndrome in women. J Res Med Sci. 2011; 16(12): 1532-40. [View at Publisher] [PMID] [Google Scholar]
19. Henneman P, Janssens AC, Zillikens MC, Frolich M, Frants RR, Oostra BA, et al. Menopause impacts the relation of plasma adiponectin levels with the metabolic syndrome. J Intern Med. 2010; 267(4): 402-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Haluzík M, Parízková J, Haluzík MM. Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res. 2004; 53(2): 123-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens). 2012; 11(1): 8-20. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond). 2008; 114(5): 361-74. [View at Publisher] [DOI] [PMID] [Google Scholar]
23. Abdelgadir M, Karlsson AF, Berglund L, Berne C. Low serum adiponectin concentrations are associated with insulin sensitivity independent of obesity in Sudanese subjects with type 2 diabetes mellitus. Diabetol Metab Syndr. 2013; 5(1): 15. [View at Publisher] [DOI] [PMID] [Google Scholar]
24. Trevaskis JL, Gawronska-Kozak B, Sutton GM, McNeil M, Stephens JM, Smith SR, et al. Role of adiponectin and inflammation in insulin resistance of Mc3r and Mc4r knockout mice. Obesity (Silver Spring). 2007; 15(11): 2664-72. [View at Publisher] [DOI] [PMID] [Google Scholar]
25. Matyjaszek-Matuszek B, Lenart-Lipińska M, Kowalczyk-Bołtuć J, Szlichtyng W, Paszkowski T. Correlation between atherogenic risk and adiponectin in gestational diabetes mellitus. Ann Agric Environ Med. 2014; 21(1): 143-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
26. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem. 2003; 278(4): 2461-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
27. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001; 98(4): 2005-10. [View at Publisher] [DOI] [] [Google Scholar]
28. Mirza S, Hossain M, Mathews C, Martinez P, Pino P, Gay JL, et al. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine. 2012; 57(1): 136-42. [View at Publisher] [DOI] [PMID] [Google Scholar]
29. Buyukbese MA, Cetinkaya A, Kocabas R, Guven A, Tarakcioglu M. Leptin levels in obese women with and without type 2 diabetes mellitus. Mediators Inflamm. 2004; 13(5-6): 321-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
30. García-Jiménez S, Bernal Fernández G, Martínez Salazar MF, Monroy Noyola A, Toledano Jaimes C, Meneses Acosta A, Gonzalez Maya L, Aveleyra Ojeda E, Terrazas Meraz MA, Boll MC, Sánchez-Alemán MA. Serum leptin is associated with metabolic syndrome in obese Mexican subjects. J Clin Lab Anal. 2015; 29(1): 5-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
31. Bălăşoiu M, Bălăşoiu AT, Stepan AE, Dinescu SN, Avrămescu CS, Dumitrescu D, et al. Proatherogenic adipocytokines levels in metabolic syndrome. Rom J Morphol Embryol. 2014; 55(1): 29-33. [View at Publisher] [PMID] [Google Scholar]
32. Mohammadzadeh G, Zarghami N. Serum leptin level is reduced in non-obese subjects with type 2 diabetes. Int J Endocrinol Metab. 2013; 11(1): 3-10. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.